- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech High Insider Buying
Hong Kong Pharmaceuticals & Biotech High Insider Buying
Results
9
Stocks with high levels of insider buying the past 3 months and good analyst coverage.
9 companies
Sino Biopharmaceutical
Market Cap: HK$127.3b
An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
1177
HK$7.12
7D
2.3%
1Y
115.1%
CSPC Pharmaceutical Group
Market Cap: HK$90.0b
An investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally.
1093
HK$7.87
7D
3.8%
1Y
53.7%
Grand Pharmaceutical Group
Market Cap: HK$29.8b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials.
512
HK$8.51
7D
0.1%
1Y
84.6%
CARsgen Therapeutics Holdings
Market Cap: HK$9.7b
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China.
2171
HK$17.48
7D
6.5%
1Y
177.9%
Jacobio Pharmaceuticals Group
Market Cap: HK$5.4b
An investment holding company, engages in the in-house discovery and development of oncology therapies.
1167
HK$6.87
7D
0.1%
1Y
306.5%
Clover Biopharmaceuticals
Market Cap: HK$3.4b
A biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally.
2197
HK$2.61
7D
19.2%
1Y
755.7%
Transcenta Holding
Market Cap: HK$1.3b
A clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of various drugs for unmet medical needs in the People’s Republic of China and the United States.
6628
HK$2.82
7D
-0.7%
1Y
235.7%
Kintor Pharmaceutical
Market Cap: HK$1.0b
A clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People’s Republic of China.
9939
HK$2.16
7D
17.4%
1Y
105.7%
PuraPharm
Market Cap: HK$152.1m
An investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally.
1498
HK$0.39
7D
-4.9%
1Y
-40.8%